Leapfrog Bio

Leapfrog Bio is a private, pre-clinical stage biotech leveraging its novel OncoSLX platform to discover and develop precision oncology therapies. The company's approach screens clinically tested drugs against a wide array of cancer driver mutations to identify potent pharmacogenetic relationships, aiming to accelerate development and reduce translational risk. Its lead program, LFB190, is a BET inhibitor targeting EP300 loss-of-function mutant cancers, with a Phase 1b/2a trial planned for 2026. A second program, LFB083, targets PIK3CA gain-of-function mutations, representing a significant unmet need in cancers like breast cancer.

OncoSLX platform: A proprietary pharmacologically-based screening platform that uses pooled CRISPR and isogenic models to test clinical-stage small molecules against cancer driver mutations, identifying pharmacogenetic relationships beyond conventional synthetic lethality.

Leapfrog competes in the crowded precision oncology space but differentiates by focusing on loss-of-function mutations and drug repurposing. It faces competition from companies developing novel BET and PI3K inhibitors, as well as other platforms focused on synthetic lethality. Its success hinges on demonstrating superior efficacy in specific genetic subsets.